Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Vanguard Market Neutral Fund Investor Shares (VMNFX)

12.01
Net Asset Value
+0.17%
1 Day
-0.99%
Year-to-Date
Overall Morningstar Rating
Market neutral
Style or Category
No Load
Sales Expenses
1.46%
Expense Ratio
Average
Morningstar Risk Rating™
Investment Objective The investment seeks to provide long-term capital appreciation while limiting exposure to general stock market risk. The fund follows a market neutral strategy, which the managers define as a strategy designed to produce a portfolio that is neutral with respect to general stock market risk (sometimes referred to as beta neutrality). Beta is a measure of a portfolio's volatility relative to the volatility of the general stock market. The fund, as a whole, does not seek to adhere to any other definition of market neutrality.

Performance

1 month-2.44% 3 years+4.23%
3 months-3.62% 5 years+3.65%
1 year+4.73% Since inception+3.11%
Data through --

Peer Comparisonvs. Market neutral

 VMNFXCategory
Performance 5-yr return+3.65%+1.10%
Expense ratio1.46%1.65%
Risk 5 year sharpe ratio0.900.08
Net assets$1.6B$463.4M
Average market cap$3.8B$27.1B
Average P/E12.814.7
Portfolio turnover68%68%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyVanguard
Fund manager & tenureJames Stetler / 4 Years
Minimal initial investment$250,000.00
Minimum IRA investment--

Holdings

Cash110.55%
U.S. stock0.65%
International stock0.00%
Fixed income0.00%
Other0.00%
Top 5 Sectors
Portfolio weighting
Financial service 18.50%
Industrial materials 13.92%
Consumer goods 12.61%
Healthcare 9.89%
Consumer service 9.29%
Top 10 Holdings
Portfolio weighting
ACAD ACADIA Pharmaceuticals Inc24.72%
VA Virgin America Inc23.54%
AMED Amedisys Inc23.05%
DYN Dynegy Inc22.80%
CSGS CSG Systems International Inc22.33%
ENV Envestnet Inc21.91%
FDC First Data Corp21.90%
NBIX Neurocrine Biosciences Inc21.89%
NTCT NetScout Systems Inc21.72%
IPHI Inphi Corp21.44%

Partner Offers